L’Imperio, Vincenzo http://orcid.org/0000-0002-9284-2998
Cazzaniga, Giorgio http://orcid.org/0000-0001-5373-0611
Mannino, Mauro
Seminati, Davide http://orcid.org/0000-0002-2166-301X
Mascadri, Francesco
Ceku, Joranda
Casati, Gabriele
Bono, Francesca
Eloy, Catarina
Rocco, Elena Guerini
Frascarelli, Chiara
Fassan, Matteo
Malapelle, Umberto
Pagni, Fabio http://orcid.org/0000-0001-9625-1637
Funding for this research was provided by:
Ministero dell’Istruzione, dell’Università e della Ricerca (Dipartimenti di Eccellenza 2023-2027 (l. 232/2016, art. 1, commi 314 - 337))
Università degli Studi di Milano - Bicocca
Article History
Received: 4 January 2024
Revised: 19 February 2024
Accepted: 20 March 2024
First Online: 26 March 2024
Declarations
:
: Approval was obtained from the local ethics committee (prot. 35859, 24/10/2022).
: UM received personal fees (as consultant and/or speaker bureau) from Amgen, Boehringer Ingelheim, Diaceutics, Eli Lilly, GSK, Merck, MSD, Roche, Thermo Fisher Scientific, and from AstraZeneca, Diatech, Hedera, Janssen, and Novartis unrelated to the current work. FP received personal fees (as consultant and/or speaker bureau) from Amgen, Eli Lilly, GSK, Merck, MSD, Roche, AstraZeneca, Diatech, Janssen, Novartis, Diapath, and LogiBiotech unrelated to the current work. VL received personal fees (as consultant and/or speaker bureau) from Eli Lilly, Roche, and Novartis unrelated to the current work.